Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 276,049	$ 216,186
Accounts receivable, net	2,378	121
Inventories	6,504	0
Available-for-sale securities	132,778	49,997
Prepaid research and development expenses	5,465	6,427
Other current assets	5,645	6,679
Total current assets	428,819	279,410
Property and equipment, net	4,226	4,440
Intangible assets, net	20,675	21,047
Goodwill	58,015	57,192
Other assets	24,879	2,468
Total assets	536,614	364,557
Current liabilities:
Accounts payable	23,918	10,912
Accrued research and development expenses	25,868	35,198
Other accrued expenses	9,083	19,487
Total current liabilities	58,869	65,597
Deferred income taxes, net	207	0
Milestone liability	20,528	20,062
Convertible senior notes	281,443	281,126
Deferred rent, long-term	1,358	1,406
Total liabilities	362,405	368,191
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.001 par value per share, 100,000,000 shares authorized at March 31, 2017 and December 31, 2016; 44,769,756 and 38,724,090 shares issued and outstanding at March 31, 2017 and December 31, 2016 respectively	45	39
Additional paid-in capital	1,410,789	1,174,950
Accumulated other comprehensive loss	(47,118)	(47,580)
Accumulated deficit	(1,189,507)	(1,131,043)
Total stockholders' equity (deficit)	174,209	(3,634)
Total liabilities and stockholders' equity (deficit)	$ 536,614	$ 364,557